Physician profile
Anna Litvak
NPI 1093784688
$22,565.96
in general payments reported to CMS, 2019-2025
66 companies · $5,564 in 2025
The $5,564 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,195 · 2020: $378 · 2021: $1,352 · 2022: $3,424 · 2023: $4,147 · 2024: $5,506 · 2025: $5,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,907.70 |
| Education | $309.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,455.12 | 2021-2025 | |
| Biogen, INC. | $2,419.66 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Pfizer INC. | $1,233.89 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,100.65 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Ucb, INC. | $1,084.08 | 2019-2025 | Rystiggo, Zilbrysq, Briviact |
| Novartis Pharmaceuticals Corporation | $973.03 | 2019-2025 | |
| Celgene Corporation | $888.14 | 2021-2025 | Zeposia |
| Mdd US Operations, LLC | $804.32 | 2019-2025 | Apokyn, Gocovri, Gocovri |
| Lilly USA, LLC | $781.33 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Lundbeck LLC | $719.60 | 2023-2025 | Vyepti, Rexulti |
| Amneal Pharmaceuticals LLC | $639.01 | 2019-2025 | Crexont, Rytary, Ongentys |
| Eisai INC. | $539.37 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $468.27 | 2023-2025 | Rexulti, Nuedexta |
| Emd Serono, INC. | $408.56 | 2019-2025 | Mavenclad, Mavenclad |
| Sk Life Science, INC. | $391.12 | 2020-2025 |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $388.00 | 2019-2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $368.96 | 2022-2025 | Ultomiris |
| Kyowa Kirin, INC. | $343.49 | 2019-2024 | Nourianz |
| Amgen INC. | $333.49 | 2019-2025 | Uplizna, Aimovig |
| Vanda Pharmaceuticals INC. | $329.18 | 2024-2025 | Ponvory |
| Daiichi Sankyo INC. | $313.63 | 2019 | |
| Neurocrine Biosciences, INC. | $298.18 | 2022-2025 | Ingrezza, Ongentys |
| Genzyme Corporation | $288.36 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $273.30 | 2019-2025 | Qelbree |
| Argenx US, INC. | $257.16 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Genentech USA, INC. | $244.01 | 2020-2025 | Ocrevus, Ocrevus Zunovo |
| Allergan, INC. | $229.50 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $185.02 | 2023-2025 | Wainua, Enhertu, Evusheld |
| Takeda Pharmaceuticals U.S.A., INC. | $181.94 | 2023-2024 | Hyqvia, Gammagard |
| Sunovion Pharmaceuticals INC. | $178.88 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $160.23 | 2024-2025 | Xeomin, Inbrija |
| Tg Therapeutics, INC. | $157.04 | 2023-2025 | |
| Avanir Pharmaceuticals, INC. | $150.44 | 2019-2022 | |
| Boston Scientific Corporation | $144.26 | 2024-2025 | General - Therapies, General - Pain Management |
| Axsome Therapeutics, INC. | $142.58 | 2025 | Symbravo |
| Acorda Therapeutics, INC | $137.30 | 2019-2023 | Inbrija |
| Biohaven Pharmaceuticals, INC. | $121.26 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $105.10 | 2019-2024 | Dysport |
| Janssen Pharmaceuticals, INC | $102.42 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $100.49 | 2022 | |
| Cala Health, INC. | $97.19 | 2023 | Cala Trio, Cala Kiq |
| Arbor Pharmaceuticals, INC. | $93.81 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $80.32 | 2021-2025 | Zeposia |
| Impel Pharmaceuticals INC. | $66.53 | 2022-2023 | Trudhesa |
| Azurity Pharmaceuticals, INC. | $62.41 | 2023-2025 | Horizant, Horizant |
| Tanabe Pharma America, INC. | $59.71 | 2019-2024 | |
| Livanova USA, INC. | $57.43 | 2022-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Alnylam Pharmaceuticals INC. | $52.96 | 2024 | Onpattro |
| Grifols USA, LLC | $52.48 | 2019 | |
| Life Molecular Imaging LTD | $48.41 | 2024-2025 | Neuraceq |
| Catalyst Pharmaceuticals, INC. | $43.60 | 2019-2024 | |
| Greenwich Biosciences, INC. | $41.51 | 2019-2020 | |
| Banner Life Sciences, LLC | $39.83 | 2022 | |
| Avion Pharmaceuticals | $38.97 | 2022 | |
| Insightec,INC | $37.84 | 2024 | Exablate |
| Vertical Pharmaceuticals, LLC | $34.91 | 2019 | |
| Horizon Therapeutics Plc | $33.74 | 2022-2023 | Uplizna |
| Ge Healthcare | $29.42 | 2020 | |
| Janssen Biotech, INC. | $23.85 | 2025 | |
| Amylyx Pharmaceuticals, INC. | $21.37 | 2023 | Relyvrio |
| Cycle Pharmaceuticals INC | $20.87 | 2025 | Tascenso Odt, Bafiertam |
| Neuropace, INC. | $20.87 | 2019 | |
| Merz North America, INC. | $20.80 | 2019 | |
| Strongbridge US INC. | $18.73 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.47 | 2024 | |
| Shire North American Group INC | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Litvak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.